As the COVID-19 pandemic continued in 2021, the off-patent industry stepped in to provide relief in a variety of ways, whether through securing supplies of essential medicines or helping to manufacture and distribute newly-developed treatments.

The private specialty pharma is shopping for a transformative deal or a series of smaller deals that will diversify the company into a new area outside of pain and CNS disorders, CEO Mark Timney says during interview.

Newly appointed senior VP-R&D Alan Dunton is charged with curing the firm's dependency on pain products.

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, Pharmaceuticals, and Research/Analytical Tools – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in September 2015.